FDA Advisory Panel To Review Cell Therapeutics' Pixantrone
The Food and Drug Administration will select an advisory panel to review Cell Therapeutics Inc.'s (Nasdaq: CTIC) lymphoma treatment pixantrone due to safety concerns. The stock price plummeted 34 cents to 72 cents.
0 TrackBacks
Listed below are links to blogs that reference this entry: FDA Advisory Panel To Review Cell Therapeutics' Pixantrone.
TrackBack URL for this entry: http://blog.marketminute.com/cgi-bin/mt/mt-tb.cgi/6365
